{"title":"抗血小板疗法对 COVID-19 的影响","authors":"Ecaterina Scarlatescu, Toshiaki Iba","doi":"10.14789/jmj.JMJ24-0004-P","DOIUrl":null,"url":null,"abstract":"<p><p>Platelets are one of the major targets of SARS-CoV-2. Activated platelets release prothrombotic substances, express adhesion molecules, and activate coagulation, thereby contributing to the thrombotic tendency in COVID-19. However, the antiplatelet therapy is not recommended in the current international guidelines. We think that the initiation timing and the target severity are the causes of the failure in clinical trials. As shown in the clinical studies that examined the effects of anticoagulants, early initiation in moderate severity is necessary for the success of antithrombotic therapy. Future trials are warranted to study the effects of antiplatelets in such conditions.</p>","PeriodicalId":52660,"journal":{"name":"Juntendo Iji Zasshi","volume":"70 2","pages":"118-120"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487358/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Effect of Antiplatelet Therapy on COVID-19.\",\"authors\":\"Ecaterina Scarlatescu, Toshiaki Iba\",\"doi\":\"10.14789/jmj.JMJ24-0004-P\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Platelets are one of the major targets of SARS-CoV-2. Activated platelets release prothrombotic substances, express adhesion molecules, and activate coagulation, thereby contributing to the thrombotic tendency in COVID-19. However, the antiplatelet therapy is not recommended in the current international guidelines. We think that the initiation timing and the target severity are the causes of the failure in clinical trials. As shown in the clinical studies that examined the effects of anticoagulants, early initiation in moderate severity is necessary for the success of antithrombotic therapy. Future trials are warranted to study the effects of antiplatelets in such conditions.</p>\",\"PeriodicalId\":52660,\"journal\":{\"name\":\"Juntendo Iji Zasshi\",\"volume\":\"70 2\",\"pages\":\"118-120\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487358/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Juntendo Iji Zasshi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14789/jmj.JMJ24-0004-P\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Juntendo Iji Zasshi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14789/jmj.JMJ24-0004-P","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Platelets are one of the major targets of SARS-CoV-2. Activated platelets release prothrombotic substances, express adhesion molecules, and activate coagulation, thereby contributing to the thrombotic tendency in COVID-19. However, the antiplatelet therapy is not recommended in the current international guidelines. We think that the initiation timing and the target severity are the causes of the failure in clinical trials. As shown in the clinical studies that examined the effects of anticoagulants, early initiation in moderate severity is necessary for the success of antithrombotic therapy. Future trials are warranted to study the effects of antiplatelets in such conditions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
